IRB #

STUDY00018937

Title

A Phase II Trial of Perioperative CV301 Vaccination in Combination with Nivolumab and Systemic Chemotherapy for Resectable Hepatic-Limited Metastatic Colorectal Cancer

Principal Investigator

Skye Mayo

Study Purpose

To determine if pre-surgery vaccination with CV301 in combination with Nivolumab, chemotherapy, and surgery will improve the overall survivial compared to pre-surgery Nivolumab, chemotherapy, and surgery in patients with liver-limited (hepatic-limited) metastatic colorectal cancer.

Medical Condition(s)

Hepatic-limited colorectal cancer
CV301

Eligibility Criteria

-Age ≥ 18 years at the time of consent.
-ECOG Performance Status of ≤ 2 and/or sufficient to undergo both perioperative systemic chemotherapy and hepatic surgery as determined by surgical and medical oncology evaluations.
-Histologically confirmed hepatic-limited metastatic colorectal cancer

Age Range

18 - 150

Healthy Volunteers Needed

No

Duration of Participation

7 years

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080

Sponsor

Hoosier Cancer Research Network, Inc.

Recruitment End

08/20/2028

Compensation Provided

No


Go Back